Menu
Recruiting NCT05706558

Retrospective Review of Esophageal Cancer at MSKCC

— Observational Esophageal Cancer Esophagus Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Esophagectomy.
Who it may be relevant to
Registry conditions: Esophageal Cancer, Esophagus Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.

Interventions

  • Procedure Esophagectomy
    Esophagectomy

Primary outcome measures

  • . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) [Time frame: Up to 2 years]
Secondary outcome measures (4)
  • Overall survival and progression-free survival (measured from date of surgery) [Time frame: Up to 2 years]
  • Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate). [Time frame: Up to 2 years]
  • Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment). [Time frame: Up to 2 years]
  • Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy). [Time frame: Up to 2 years]

Eligibility criteria

Inclusion criteria

  • Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
  • Pathologic staged T3 tumors (pT3)

Exclusion criteria

  • Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
  • Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
  • Patients undergoing salvage esophagectomy
  • Evidence of distant metastatic disease
  • Patients with a positive proximal or distal margin

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York

Identifiers

NCT: NCT05706558 · 16-1631

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗